Tolerability of the oral fluoropyrimidine S-1 after hand-foot syndrome-related discontinuation of capecitabine in western cancer patients

Authors

  • J. J. M. Kwakman Department of Medical Oncology, Academic Medical Center, University of Amsterdam, Amsterdam, The Netherlands
  • A. Baars Department of Medical Oncology, Hospital Gelderse Vallei, Ede, The Netherlands
  • H. Boot Department of Gastroenterology and Hepatology, The Netherlands Cancer Institute, Amsterdam, The Netherlands
  • J. F. M. Pruijt Department of Medical Oncology, Jeroen Bosch Hospital, Den Bosch, The Netherlands
  • S. B. Winther Department of Medical Oncology, Odense University Hospital, Odense, Denmark
  • P. Pfeiffer Department of Medical Oncology, Odense University Hospital, Odense, Denmark
  • C. J. A. Punt Department of Medical Oncology, Academic Medical Center, University of Amsterdam, Amsterdam, The Netherlands

DOI:

https://doi.org/10.1080/0284186X.2016.1278459

Abstract

No abstract available

Downloads

Download data is not yet available.

Downloads

Additional Files

Published

2017-07-03

How to Cite

Kwakman, J. J. M., Baars, A., Boot, H., Pruijt, J. F. M., Winther, S. B., Pfeiffer, P., & Punt, C. J. A. (2017). Tolerability of the oral fluoropyrimidine S-1 after hand-foot syndrome-related discontinuation of capecitabine in western cancer patients. Acta Oncologica, 56(7), 1023–1026. https://doi.org/10.1080/0284186X.2016.1278459

Issue

Vol. 56 No. 7 (2017): Acta Oncologica

Section

Articles